A Phase I Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic Graft-versus-Host-Disease
Phase of Trial: Phase I
Latest Information Update: 14 Jul 2017
At a glance
- Drugs Interleukin-2 (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 10 Aug 2015 Status changed from suspended to recruiting as per ClinicalTrials.gov record.
- 29 Jun 2015 Status changed from recruiting to suspended, according to ClinicalTrials.gov record.